Evaxion Biotech A/S – NASDAQ:EVAX
Founder-led company
Evaxion Biotech A/S stock price today
$3.1
+2.04
+192.45%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Evaxion Biotech A/S stock price monthly change
-67.88%
month
Evaxion Biotech A/S stock price quarterly change
-67.88%
quarter
Evaxion Biotech A/S stock price yearly change
+51.43%
year
Evaxion Biotech A/S key metrics
Market Cap | 47.07M |
Enterprise value | N/A |
P/E | -1.06 |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | 2.05 |
PEG ratio | 0.01 |
EPS | -5.56 |
Revenue | N/A |
EBITDA | -14.68M |
Income | -14.72M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeEvaxion Biotech A/S stock price history
Evaxion Biotech A/S stock forecast
Evaxion Biotech A/S financial statements
| Jun 2023 | 0 | -5.68M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.67M | |
| Dec 2023 | 73.59K | -4.56M | -6195.96% |
| Mar 2024 | 50.88K | 1.19M | 2346.65% |
| 2025 | 13.75M | -5.76M | -41.9% |
|---|---|---|---|
| 2026 | 63.58M | 30.90M | 48.6% |
| 2027 | 29.12M | 355.36K | 1.22% |
| 2028 | 91.04M | 10.11M | 11.11% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 16754000 | 14.21M | 84.87% |
|---|---|---|---|
| Sep 2023 | -75087000 | 14.67M | -19.55% |
| Dec 2023 | 12888619 | 17.61M | 136.69% |
| Mar 2024 | 22653821 | 20.04M | 88.51% |
| Mar 2023 | 0 | 0 | 0 |
|---|---|---|---|
| Jun 2023 | 0 | 0 | 0 |
| Sep 2023 | -4.39M | -65K | 96K |
| Dec 2023 | -2.00M | 1K | 5.25M |
Evaxion Biotech A/S alternative data
| Aug 2023 | 63 |
|---|---|
| Sep 2023 | 63 |
| Oct 2023 | 63 |
| Nov 2023 | 63 |
| Dec 2023 | 63 |
| Jan 2024 | 63 |
| Feb 2024 | 63 |
| Mar 2024 | 63 |
| Apr 2024 | 63 |
| May 2024 | 49 |
| Jun 2024 | 49 |
| Jul 2024 | 49 |
Evaxion Biotech A/S other data
0.27%
-0.21%
of EVAX is owned by hedge funds
63.66K
-29.23K
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2023 2 Apr 2024 | Q4 2023 Earnings Call Transcript |
| Q2 2023 22 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Q2 2022 10 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 11 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Lars Aage-Staal Wegner M.D. (1975) Chief Executive Officer | $942,000 |
Mr. Andreas Holm Mattsson (1976) Co-Founder & Chief Innovation Officer | $213,000 |
Dr. Niels Iversen Moeller M.D. (1979) Co-Founder, Chief Bus. Officer, Interim Chief Financial Officer | $213,000 |
-
What's the price of Evaxion Biotech A/S stock today?
One share of Evaxion Biotech A/S stock can currently be purchased for approximately $3.1.
-
When is Evaxion Biotech A/S's next earnings date?
Unfortunately, Evaxion Biotech A/S's (EVAX) next earnings date is currently unknown.
-
Does Evaxion Biotech A/S pay dividends?
No, Evaxion Biotech A/S does not pay dividends.
-
How much money does Evaxion Biotech A/S make?
Evaxion Biotech A/S has a market capitalization of 47.07M.
-
What is Evaxion Biotech A/S's stock symbol?
Evaxion Biotech A/S is traded on the NASDAQ under the ticker symbol "EVAX".
-
What is Evaxion Biotech A/S's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Evaxion Biotech A/S?
Shares of Evaxion Biotech A/S can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Evaxion Biotech A/S's key executives?
Evaxion Biotech A/S's management team includes the following people:
- Dr. Lars Aage-Staal Wegner M.D. Chief Executive Officer(age: 50, pay: $942,000)
- Mr. Andreas Holm Mattsson Co-Founder & Chief Innovation Officer(age: 49, pay: $213,000)
- Dr. Niels Iversen Moeller M.D. Co-Founder, Chief Bus. Officer, Interim Chief Financial Officer(age: 46, pay: $213,000)
-
Is Evaxion Biotech A/S founder-led company?
Yes, Evaxion Biotech A/S is a company led by its founders Mr. Andreas Holm Mattsson and Dr. Niels Iversen Moeller M.D..
-
How many employees does Evaxion Biotech A/S have?
As Jul 2024, Evaxion Biotech A/S employs 49 workers, which is 22% less then previous quarter.
-
When Evaxion Biotech A/S went public?
Evaxion Biotech A/S is publicly traded company for more then 4 years since IPO on 5 Feb 2021.
-
What is Evaxion Biotech A/S's official website?
The official website for Evaxion Biotech A/S is evaxion-biotech.com.
-
How can i contact Evaxion Biotech A/S?
Evaxion Biotech A/S can be reached via phone at +45 53 53 18 50.
Evaxion Biotech A/S company profile:
Evaxion Biotech A/S
evaxion-biotech.comExchange:
NASDAQ
Full time employees:
49
Industry:
Biotechnology
Sector:
Healthcare
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
Dr. Neergaards Vej
Horsholm, 2970
Horsholm, 2970
CIK: 0001828253
ISIN: US29970R2040
CUSIP: 29970R105
